|
| 34874116 | Canakinumab's Effect Against Subsequent Gout Flares and High-Sensitivity C-Reactive Protein Levels: A Causal Mediation Analysis. | Arthritis Care and Research | 2023 |
| 36351465 | Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers. | J Am Coll Cardiol | 2023 |
| 36331823 | Interplay of Atherogenic Particle Number and Particle Size and the Risk of Coronary Heart Disease. | Clin Chem | 2023 |
| 36450449 | Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis. | Annals of the Rheumatic Diseases | 2023 |
| 36449307 | Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte Ratio: A Secondary Analysis of the RESCUE Clinical Trial. | JAMA Cardiology | 2023 |
| 37934948 | Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial. | Blood Adv | 2023 |
| 38028628 | Gene-educational attainment interactions in a multi-population genome-wide meta-analysis identify novel lipid loci. | Front Genet | 2023 |
| 37927208 | Effect of canakinumab on frailty: A post hoc analysis of the CANTOS trial. | | 2023 |
| 37565977 | Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction. | JACC Heart Fail | 2023 |
| 37782696 | The Time to Initiate Anti-Inflammatory Therapy for Patients With Chronic Coronary Atherosclerosis Has Arrived. | | 2023 |
| 37558377 | Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week. | | 2023 |
| 37871757 | Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention. | | 2023 |
| 37218417 | C-Reactive Protein and Risk of Cardiovascular Events and Mortality in Patients with Various Cardiovascular Disease Locations. | | 2023 |
| 36778599 | Candidate loci shared among periodontal disease, diabetes and bone density. | Front Endocrinol (Lausanne) | 2023 |
| 36908662 | Coronary Flow Reserve, Inflammation, and Myocardial Strain: The CIRT-CFR Trial. | | 2023 |
| 36512683 | Interactions Between Genetic Risk and Diet Influencing Risk of Incident Female Gout: Discovery and Replication Analysis of Four Prospective Cohorts. | Arthritis Rheumatol | 2023 |
| 36893777 | Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. | Lancet | 2023 |
| 37398003 | Whole genome analysis of plasma fibrinogen reveals population-differentiated genetic regulators with putative liver roles. | medRxiv | 2023 |
| 36813656 | Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial. | J Clin Lipidol | 2023 |
| 37189091 | Clinically stable covid-19 patients presenting to acute unscheduled episodic care venues have increased risk of hospitalization: secondary analysis of a randomized control trial. | BMC Infect Dis | 2023 |
| 37354546 | Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. | | 2023 |
| 36787889 | Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction. | | 2023 |
| 37527449 | Effect Measure Modification by Covariates in Mediation: Extending Regression-based Causal Mediation Analysis. | | 2023 |
| 37503126 | Understanding the genetic complexity of puberty timing across the allele frequency spectrum. | medRxiv | 2023 |
| 34931349 | Dissecting the IL-6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R. | British Journal of Clinical Pharmacology | 2022 |
| 35974141 | Genome-wide meta-analyses reveal novel loci for verbal short-term memory and learning. | Mol Psychiatry | 2022 |
| 36041476 | Autoimmune diseases and atherothrombotic risk. | Lancet, The | 2022 |
| 35524914 | ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future. | Current Atherosclerosis Reports | 2022 |
| 35762321 | Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. | Circulation | 2022 |
| 35697829 | Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals. | Commun Biol | 2022 |
| 35385050 | TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial. | JAMA Cardiology | 2022 |
| 36154123 | Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors. | Circulation | 2022 |
| 36342113 | Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. | New England Journal of Medicine | 2022 |
| 35943897 | Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy. | European Heart Journal | 2022 |
| 36134918 | Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS. | Diabetes Care | 2022 |
| 36064794 | Targeting innate immunity-driven inflammation in CKD and cardiovascular disease. | Nature Reviews Nephrology | 2022 |
| 35862024 | Association of Physical Activity With Bioactive Lipids and Cardiovascular Events. | Circ Res | 2022 |
| 35671649 | Genetics are not likely to offer clinically useful predictions for elevated liver enzyme levels in patients using low dose methotrexate. | Semin Arthritis Rheum | 2022 |
| 35358342 | Clinical predictors of COVID-19 severity and bleeding in the ACTIV-4B COVID-19 outpatient thrombosis prevention trial. | American Journal of Hematology | 2022 |
| 36439649 | Earlier treatment in adults with high lifetime risk of cardiovascular diseases: What prevention trials are feasible and could change clinical practice? Report of a National Heart, Lung, and Blood Institute (NHLBI) Workshop. | Am J Prev Cardiol | 2022 |
| 35779559 | Antithrombotic prophylaxis for symptomatic outpatients with COVID-19: less is consistently more. | Lancet Haematology,The | 2022 |
| 36774119 | Sugar-Sweetened Beverage Consumption and Plasma Lipoprotein Cholesterol, Apolipoprotein, and Lipoprotein Particle Size Concentrations in US Adults. | J Nutr | 2022 |
| 33705531 | Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. | Cardiovascular Research | 2022 |
| 35315488 | Thromboinflammation and Antithrombotics in COVID-19: Accumulating Evidence and Current Status. | JAMA - Journal of the American Medical Association | 2022 |
| 35277540 | Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1. | Sci Rep | 2022 |
| 34789503 | Obesity Partially Mediates the Diabetogenic Effect of Lowering LDL Cholesterol. | Diabetes Care | 2022 |
| 34718444 | Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis. | Cardiovascular Research | 2022 |
| 35165698 | Proteomics for the prediction and prevention of atherosclerotic disease. | European Heart Journal | 2022 |
| 35108398 | Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles. | Clin Pharmacol Ther | 2022 |
| 34635557 | Phenotypic and Genotypic Associations Between Migraine and Lipoprotein Subfractions. | Neurology | 2021 |